Last updated: September 8, 2026
Insulin lispro is a mature rapid-acting insulin franchise dominated by Eli Lilly’s Humalog, with growing sales exposure to lower-priced versions, automated insulin-delivery systems and newer formulations such as Lyumjev. Humalog revenue has declined from approximately $2.8 billion in 2019 to roughly $1.9 billion in 2024 as pricing pressure, authorized generic substitution and competing insulin products reduced Lilly’s realized price and volume.
The principal commercial risks are contracting pressure, government price negotiation and reimbursement changes rather than near-term patent expiry. The principal growth opportunities are concentrated in faster-acting formulations, concentrated presentations, pump use and international markets.
What is insulin lispro and which products contain it?
Insulin lispro is a recombinant rapid-acting human insulin analog. It differs from human insulin by reversing the amino acids at positions B28 and B29, reducing self-association and allowing faster absorption after subcutaneous administration.
The principal insulin lispro products are:
| Product |
Company |
Regulatory status |
Primary use |
| Humalog, insulin lispro injection |
Eli Lilly |
FDA-approved NDA 020563, 1996 |
Mealtime insulin |
| Humalog U-200 KwikPen |
Eli Lilly |
FDA-approved presentation |
Patients requiring higher doses |
| Humalog U-100 vial and pen |
Eli Lilly |
FDA-approved presentations |
Multiple delivery formats |
| Admelog, insulin lispro injection |
Sanofi |
FDA-approved 2017 under 505(b)(2) |
Lower-priced rapid-acting insulin |
| Lyumjev, insulin lispro-aabc |
Eli Lilly |
FDA-approved 2020 |
Ultra-rapid mealtime insulin |
| Authorized generic insulin lispro |
Eli Lilly |
Marketed since 2019 |
Lower-price Humalog alternative |
Lyumjev contains the same insulin lispro active molecule with formulation excipients intended to accelerate absorption. It is a separate product from Humalog and has its own FDA approval and product-specific intellectual-property position.
How has the insulin lispro market performed financially?
Lilly’s Humalog revenue has followed a sustained decline as the product moved from premium branded insulin toward a mature, heavily rebated category.
| Year |
Humalog revenue, approximate |
Year-over-year direction |
Principal driver |
| 2019 |
$2.8 billion |
Decline begins |
Rebates and insulin pricing pressure |
| 2020 |
$2.6 billion |
Down |
Lower realized price and competition |
| 2021 |
$2.5 billion |
Down |
U.S. contracting pressure |
| 2022 |
$2.4 billion |
Down |
Lower net price and channel pressure |
| 2023 |
$2.2 billion |
Down materially |
Authorized generic and reimbursement changes |
| 2024 |
Approximately $1.9 billion |
Down materially |
Price reductions, channel mix and lower volume |
Source: Eli Lilly annual reports and Form 10-K filings for the respective years.
From 2019 to 2024, Humalog revenue fell by approximately one-third. The decline does not represent a collapse in insulin lispro demand. It reflects a shift in value capture from the manufacturer to payers, pharmacy benefit managers, government programs and lower-priced channels.
Lilly’s insulin lispro economics are affected by:
- Gross-to-net deductions from rebates and discounts.
- The company’s own authorized generic.
- Medicaid rebate obligations.
- Medicare Part D and other government pricing rules.
- High-deductible plan exposure.
- Competitive formulary placement against insulin aspart and insulin glulisine.
- Lower list prices and capped patient out-of-pocket costs.
The authorized generic protects Lilly’s volume and limits the risk that a competing manufacturer captures the entire low-price segment. It also cannibalizes Humalog’s branded revenue and carries a lower net price.
What is the commercial role of Lilly’s authorized generic insulin lispro?
Lilly introduced an authorized generic version of insulin lispro in 2019 at a list price approximately 50% below the Humalog list price. The product uses Lilly’s insulin lispro manufacturing and is commercially distinct from the Humalog brand.
The strategy has three effects:
- It gives Lilly a product for price-sensitive patients and payers.
- It reduces the commercial space available to third-party competitors.
- It shifts Lilly’s reported revenue from branded Humalog toward a lower-price product.
This approach is strategically important because insulin markets are controlled heavily by formularies and rebate contracts. A lower list price can improve access for uninsured and underinsured patients, but it does not necessarily increase Lilly’s net revenue per unit.
The authorized generic is not the same as an FDA-approved biosimilar. It is a Lilly-authorized version of the company’s insulin lispro product, while a biosimilar is developed and licensed by a separate sponsor through the FDA’s biosimilar pathway.
Which companies compete with insulin lispro?
Insulin lispro competes in the rapid-acting insulin segment rather than only against products containing the same molecule.
| Product |
Active ingredient |
Manufacturer |
Competitive position |
| Humalog |
Insulin lispro |
Eli Lilly |
Established branded franchise |
| Authorized generic lispro |
Insulin lispro |
Eli Lilly |
Lower-price Lilly channel |
| Admelog |
Insulin lispro |
Sanofi |
Direct lispro competitor |
| NovoLog/Fiasp |
Insulin aspart |
Novo Nordisk |
Major rapid-acting competitor |
| Apidra |
Insulin glulisine |
Sanofi |
Smaller rapid-acting competitor |
| Lyumjev |
Insulin lispro-aabc |
Eli Lilly |
Faster-acting premium formulation |
NovoLog and Fiasp are the strongest molecule-level and formulation-level competitors. Novo Nordisk’s strength in diabetes care, insulin pumps and endocrinology supports broad contracting competition.
Sanofi’s Admelog established a direct lower-price lispro alternative. Its market effect has been constrained by payer formularies, manufacturing economics and the high concentration of insulin distribution among a small number of manufacturers.
What is the FDA regulatory status of insulin lispro products?
Humalog was approved by the FDA in 1996 under the conventional drug approval framework applicable at the time. It was approved as a recombinant insulin analog rather than as a biosimilar.
Admelog was approved in 2017 under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. The application relied in part on FDA findings for Humalog, making it a follow-on product but not a biosimilar under the modern Public Health Service Act framework.
The FDA approved Lyumjev in 2020 for improving glycemic control in adults with diabetes. Lyumjev is available in U-100 and U-200 presentations and is used with pens, syringes and insulin pumps where the applicable labeling permits use.
Because insulin products were transitioned from the drug pathway to the biologics pathway on March 23, 2020, future insulin competitors generally use the 351(k) biosimilar pathway. That transition creates a distinction between older insulin follow-on products, such as Admelog, and future insulin biosimilars.
What is the Orange Book status of Humalog and insulin lispro?
Humalog was approved under an NDA and has historically been associated with FDA Orange Book listings. The Biologics Price Competition and Innovation Act transition changed the regulatory treatment of insulin products approved under the drug framework, but it did not erase the historical patent and exclusivity record attached to the original NDA.
The commercial importance of Orange Book listings is limited for Humalog because the core product has been marketed for nearly three decades. The principal foundational composition and formulation patents have expired or reached the end of their effective patent lives.
The remaining legal risk is more likely to involve:
- Device and delivery-system patents.
- Concentration-specific formulations.
- Pump-use configurations.
- Manufacturing processes.
- New excipient combinations.
- Lyumjev-specific formulation and method-of-use patents.
- Patent claims covering newer presentations rather than ordinary U-100 Humalog.
What patents protect insulin lispro and when does Humalog lose exclusivity?
The original Humalog patent estate was built around recombinant insulin lispro, pharmaceutical compositions and methods of treating diabetes. Representative early U.S. patents include patents assigned to Eli Lilly covering insulin lispro compositions and their therapeutic use. Those foundational patents have expired.
| Patent category |
Product relevance |
Current commercial impact |
| Insulin lispro composition patents |
Core Humalog molecule |
Generally expired |
| Recombinant production patents |
Manufacturing and expression systems |
Generally expired or commercially weak |
| Basic formulation patents |
U-100 lispro injection |
Core protection largely expired |
| Delivery-device patents |
Pens, cartridges and injectors |
May remain relevant by product and jurisdiction |
| Concentrated formulations |
Humalog U-200 |
Presentation-specific protection and regulatory barriers |
| Faster-acting formulations |
Lyumjev |
Newer formulation and method claims |
| Pump-use claims |
Humalog and Lyumjev |
Relevant to labeling and device integration |
Humalog does not have a single future “patent cliff” comparable to a recently launched biologic. Its exclusivity erosion has occurred over many years through patent expiry, follow-on competition, authorized generic commercialization and contracting pressure.
The practical market entry barrier is therefore lower for a basic insulin lispro product than for a complex injectable biologic with active composition patents. It remains high for commercial-scale production because insulin manufacturing requires validated cell-line, fermentation, purification, formulation, aseptic filling and quality-control systems.
Are there Paragraph IV challenges involving insulin lispro?
Publicly reported insulin lispro competition has been driven more by regulatory follow-on pathways and commercial price competition than by a major wave of Paragraph IV litigation.
Admelog entered through the 505(b)(2) pathway rather than through an abbreviated new drug application based on a Paragraph IV certification. Future competitors may use the 351(k) biosimilar pathway after the insulin transition, which changes the litigation framework from traditional Hatch-Waxman Paragraph IV disputes to the biologics patent dance and related patent litigation under the BPCIA.
The absence of a prominent current Paragraph IV campaign does not eliminate patent risk. A competitor could challenge patents covering:
- Lyumjev’s excipient system.
- U-200 or other concentrated formulations.
- Injection devices.
- Cartridge or pen configurations.
- Pump compatibility.
- Manufacturing methods.
The litigation value of those patents depends on whether the claims cover the active product, the commercial presentation or an optional delivery method.
What formulation patents protect Lyumjev and concentrated insulin lispro?
Lyumjev is the more defensible part of Lilly’s lispro franchise because its differentiation depends on formulation technology rather than the mature lispro molecule alone.
The product uses excipients designed to increase local dispersion and accelerate absorption after injection. Patent protection may therefore focus on:
- Specific excipient combinations.
- Concentration ranges.
- pH and stability parameters.
- Rapid-absorption pharmacokinetics.
- Methods of reducing postprandial glucose excursions.
- Use in insulin pumps or automated delivery systems.
Humalog U-200 has a separate commercial position because it reduces injection volume for patients requiring larger doses. The product’s protection can include formulation, dosing and device claims. Even after core patent expiry, regulatory approval requirements and the difficulty of matching the commercial pen presentation can delay substitution.
For both products, patent strength is higher when claims cover the approved formulation and lower when claims cover optional use cases that physicians can avoid.
What patent litigation and settlement risks affect insulin lispro?
The primary current dispute risk is likely to arise from product-specific patents rather than foundational insulin lispro patents.
A competitor could face litigation if it seeks approval for a product that copies:
- Lilly’s Lyumjev formulation.
- A concentrated lispro presentation.
- A proprietary pen or cartridge.
- A pump-compatible formulation.
- A manufacturing process protected in a major market.
Settlement agreements would be commercially significant if they include delayed entry, restricted indications, supply arrangements or licensing rights. Publicly disclosed insulin lispro competition has not produced a widely recognized settlement structure comparable to major small-molecule patent settlements.
For investors, the key issue is whether a future entrant can enter with ordinary U-100 insulin lispro while avoiding newer formulation and device patents. That scenario is more plausible than a direct early copy of Lyumjev.
How strong is the insulin lispro patent estate?
The patent estate is weak for basic insulin lispro and stronger for newer formulations and delivery systems.
| Protection layer |
Strength |
Reason |
| Core lispro molecule |
Low |
Long commercial history and expired foundational patents |
| Standard U-100 formulation |
Low to moderate |
Mature product with extensive competition |
| Authorized generic channel |
Commercially strong, not patent-based |
Lilly controls supply and branding |
| U-200 formulation |
Moderate |
Concentration and device complexity |
| Lyumjev formulation |
Moderate to strong |
Newer excipient and absorption technology |
| Delivery devices |
Moderate |
Product-specific claims can complicate substitution |
| Manufacturing know-how |
Moderate to strong |
Process validation and scale are difficult to replicate |
| Regulatory exclusivity |
Low for Humalog |
Long since expired |
| Regulatory barriers for biosimilars |
Moderate |
Comparability and manufacturing requirements remain demanding |
Patent strength does not equal commercial durability. Lilly’s most important defenses are scale, payer contracting, manufacturing quality, physician familiarity and portfolio breadth.
When does insulin lispro lose exclusivity in the United States?
Humalog’s basic regulatory and patent exclusivity has already expired. There is no single upcoming U.S. date when all insulin lispro exclusivity ends.
A practical exclusivity timeline is:
| Period |
Event |
| 1996 |
FDA approves Humalog |
| 2017 |
FDA approves Sanofi’s Admelog |
| 2019 |
Lilly launches authorized generic insulin lispro |
| March 2020 |
Insulin products transition to the biologics framework |
| 2020 |
FDA approves Lyumjev |
| 2023 onward |
Lilly faces increasing pricing and channel pressure |
| 2026 onward |
Greater potential for biosimilar and complex follow-on competition, subject to development and patent clearance |
The 2026 date is a market-development marker rather than a universal patent expiry date. Entry timing will depend on each competitor’s regulatory pathway, manufacturing readiness, patent certifications, litigation and settlement terms.
What generic entry risks exist for insulin lispro?
Generic-entry risk is moderate for standard insulin lispro and higher for newer formulations.
Standard Humalog
Risk is already present through Admelog and Lilly’s authorized generic. Further entrants would face a low core patent barrier but substantial manufacturing and commercial barriers.
Lyumjev
Risk is lower in the near term because formulation differentiation creates more opportunities for patent claims and clinical or pharmacokinetic differentiation. A competitor could enter with ordinary insulin lispro without directly substituting for Lyumjev’s ultra-rapid profile.
U-200 and delivery systems
Risk is constrained by device, manufacturing and presentation complexity. A competitor must match not only the active ingredient but also concentration, injection accuracy, stability and user interface.
Biosimilars
Future 351(k) products could create more direct competition. Biosimilar insulin sponsors must establish analytical similarity, manufacturing consistency and clinical comparability. Interchangeability, if pursued, could materially increase pharmacy-level substitution, although state substitution rules and payer contracts would still matter.
How does insulin lispro compare with insulin aspart?
| Factor |
Insulin lispro |
Insulin aspart |
| Leading brands |
Humalog, Lyumjev |
NovoLog, Fiasp |
| Main originator |
Eli Lilly |
Novo Nordisk |
| Market maturity |
Very mature |
Very mature |
| Core patent exposure |
Mostly expired |
Mostly expired for foundational products |
| Premium growth area |
Lyumjev |
Fiasp and connected-delivery use |
| Price pressure |
High |
High |
| Key commercial defense |
Lilly scale and contracting |
Novo Nordisk diabetes portfolio |
| Biosimilar risk |
Increasing |
Increasing |
| Main substitution driver |
Formulary and net price |
Formulary and net price |
The two products are clinically close enough that payer coverage and supply reliability often matter more than modest pharmacokinetic differences. Faster-acting products can support premium pricing, but their benefit must translate into formulary value and patient adherence.
What is the geographic coverage of insulin lispro patents and sales?
Humalog is sold globally, but patent and regulatory positions vary by country. The strongest commercial markets are the United States, Europe, Japan and other high-income diabetes markets.
Geographic risk differs by region:
- The United States has the highest gross sales but also the greatest rebate and policy exposure.
- Europe has tighter price controls and centralized or regional procurement.
- Emerging markets have stronger volume potential but lower prices and greater tender exposure.
- Manufacturing and supply-chain patents may have different scope across the United States, Europe, China, India and other jurisdictions.
- Biosimilar and follow-on entry timing varies by national approval and substitution rules.
International revenue is therefore more exposed to tender competition, government procurement and local manufacturing than to U.S.-style pharmacy benefit manager rebates.
What is the financial outlook for insulin lispro?
The base-case outlook is continued decline for branded Humalog revenue, partly offset by stable demand for Lilly’s broader insulin portfolio and growth from Lyumjev.
Key financial drivers include:
- Continued erosion of Humalog’s net price.
- Expansion of lower-price insulin channels.
- Greater use of Lilly’s authorized generic.
- Reimbursement changes under Medicare and Medicaid.
- Volume stability driven by diabetes prevalence and insulin dependence.
- Penetration of insulin pumps and automated insulin-delivery systems.
- Lyumjev adoption in patients seeking faster postprandial control.
- Potential biosimilar entry after the insulin regulatory transition.
- Manufacturing efficiency and supply reliability.
- Lilly’s ability to preserve preferred formulary status.
Revenue is likely to remain material because insulin lispro is a high-volume chronic therapy. Profitability will continue to depend on net price, manufacturing scale and channel mix rather than patent-protected premium pricing.
Key Takeaways
- Insulin lispro is a mature rapid-acting insulin market led by Eli Lilly’s Humalog.
- Humalog revenue declined from approximately $2.8 billion in 2019 to approximately $1.9 billion in 2024.
- The core Humalog molecule and basic formulation have largely lost meaningful patent exclusivity.
- Lilly’s authorized generic, Admelog and competing insulin aspart products have increased price pressure.
- Lyumjev has the stronger patent and differentiation profile because its value depends on a faster-absorption formulation.
- Future competition is more likely to come through 351(k) biosimilars and complex follow-on products than through traditional Paragraph IV challenges.
- Manufacturing capability, payer contracting and regulatory compliance are now more important barriers than basic molecule patents.
- Humalog revenue should continue to decline, while Lyumjev and concentrated presentations provide partial offsets.
FAQs About Insulin Lispro Patents, Competition and Revenue
Is insulin lispro a biosimilar?
No. Humalog and Admelog are not biosimilars in the current technical sense. Humalog is the originator insulin lispro product, while Admelog was approved under the 505(b)(2) pathway. Future insulin follow-on products may use the 351(k) biosimilar pathway.
Is Admelog interchangeable with Humalog?
Admelog is a follow-on insulin lispro product, but interchangeability depends on the FDA-approved labeling, pharmacy law and payer policy. It is not automatically treated as an interchangeable biosimilar in the same manner as a product designated interchangeable under section 351(k).
Does Humalog still have patent protection?
Some product, formulation, device or presentation patents may remain relevant, but the core insulin lispro patents have expired. Humalog’s principal commercial protection now comes from manufacturing scale, contracts, brand recognition and distribution.
Is Lyumjev protected by new patents?
Lyumjev may be protected by formulation, pharmacokinetic, method-of-use, device and manufacturing patents. Its protection is more relevant than Humalog’s foundational patent estate because Lyumjev launched much later and relies on formulation technology.
Will generic insulin lispro reduce Lilly revenue?
Yes. Lower-priced insulin lispro products reduce Humalog’s branded revenue and can reduce Lilly’s net price per unit. Lilly partially retains the economics through its authorized generic, but the overall franchise revenue trend remains negative.
References
- Eli Lilly and Company. (2020). 2020 annual report and Form 10-K.
- Eli Lilly and Company. (2021). 2021 annual report and Form 10-K.
- Eli Lilly and Company. (2022). 2022 annual report and Form 10-K.
- Eli Lilly and Company. (2023). 2023 annual report and Form 10-K.
- Eli Lilly and Company. (2024). 2024 annual report and Form 10-K.
- U.S. Food and Drug Administration. (1996). Humalog insulin lispro injection, NDA 020563.
- U.S. Food and Drug Administration. (2017). Admelog insulin lispro injection approval.
- U.S. Food and Drug Administration. (2020). Lyumjev insulin lispro-aabc approval.
- U.S. Food and Drug Administration. (2020). Transition of insulin products from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
